Ariana Pelosci | Authors

Articles

Capivasertib Plus Fulvestrant Reduces Risk of Disease Progression or Death in HR+/HER2– Breast Cancer

December 08, 2022

Findings from the phase 3 CAPItello-291 trial show that the combination of capivasertib plus fulvestrant achieved improvement in progression-free survival among patients with hormone-receptor–positive/HER2-negative advanced breast cancer.